Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06545331). This is a study registration, not published results. Lead sponsor: Exelixis. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 396 participants (ESTIMATED). Conditions: Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC). Interventions: DRUG: XB010; DRUG: Pembrolizumab. Primary outcome measures: Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 , 18 months; Dose-Escalation Stage: Safety of XB010 , 18 months; Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability] , 18 months; Dose-Escalation Stage: Dose intensity of XB010 [Tolerability] , 18 months; Cohort-Expansion Stage: Preliminary antitumor activity of XB010 , 24 months. Brief summary: This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.